Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Morning Vs Bedtime Aspirin Intake in Patients with Essential Thrombocythemia

Emma Cacciola, MD, Elio Gentini Cacciola, MDcal Student, Veronica Vecchio, MDcal Student, Rossella Rosari Cacciola

Blood (2018) 132 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2018-99-113446

Published: 2018

Journal Articles

Thalidomide Combined with Interferons for the Treatment of Recurrent or Refractory Non-Hodgkin's Lymphoma

Fangfang Yuan, MD, Hao Ai, Qingsong Yin, PhD, Lin Chen, MD, Ruihua Mi, Xudong Wei, Yongping Song, MD, Delong Liu, MD PhD

Blood (2018) 132 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2018-99-116131

Published: 2018

Journal Articles

Low Dose Once Daily Oral Iron Treatment of Young Children with Nutritional Iron Deficiency Anemia

Jacquelyn M. Powers, MD, Timothy L. Mccavit, MD, Leah Adix, CCRP, George R. Buchanan, MD

Blood (2015) 126 (23): 2147.

https://doi.org/10.1182/blood.V126.23.2147.2147

Published: 2015

Journal Articles

Therapeutic Superiority and Safety of Combined Hydroxyurea with Recombinant Human Erythropoietin Over Hydroxyurea in B-Thalassemia Intermedia Patients

Mohsen Saleh Elalfy, Amira Adly, Yassmine Elhanawy

Blood (2012) 120 (21): 252.

https://doi.org/10.1182/blood.V120.21.252.252

Published: 2012

Journal Articles

Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM

Massimo Offidani, Claudia Polloni, Laura Corvatta, Silvia Gentili, Anna Mele, Marino Brunori, Rita Rizzi, Massimo Catarini, Arduino Samori, Nicola Blasi, Mario Ferranti, Lara Malerba, Patrizia Caraffa, Pietro Leoni

Blood (2010) 116 (21): 3020.

https://doi.org/10.1182/blood.V116.21.3020.3020

Published: 2010

Journal Articles

Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.

Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Annalisa Citro, Paola Brasca, Luigi Montalbetti, Patrizia Zappasodi, Federica Cocito, Marzia Varettoni, MD, Mario Lazzarino, MD, Enrica Morra, MD

Blood (2009) 114 (22): 1223.

https://doi.org/10.1182/blood.V114.22.1223.1223

Published: 2009

Journal Articles

Bortezomib Plus Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity: Results of a Multicenter Study.

Shilun Chen, MD, Bin Jiang, MD, Lugui Qiu, MD, Li Yu, MD, Yuping Zhong, MD, Wen Gao, MD

Blood (2007) 110 (11): 3600.

https://doi.org/10.1182/blood.V110.11.3600.3600

Published: 2007

Journal Articles

Initial Cytoreductive Treatment with Thalidomide Plus Bolus Vincristine/Doxorubicin and Reduced Dexamethasone (T-bVAd) Followed by Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma.

Jae-Cheol Jo, Byung Wook Kang, Sun Jin Sym, Sung Sook Lee, Geundoo Jang, Dae Ho Lee, Sang-We Kim, Cheolwon Suh

Blood (2007) 110 (11): 5094.

https://doi.org/10.1182/blood.V110.11.5094.5094

Published: 2007

Journal Articles

Efficacy of the Novel Oral Iron Chelator Deferitrin in Metabolic Iron Balance Studies.

Robert W. Grady, PhD, Maria Sitarou, MD, Renzo Galanello, MD, Hannah Tamary, MD, Eliana Lai, MD, Aurelio Maggio, MD, Farrukh Shah, MD, Patricia J. Giardina, MD, Joanne M. Donovan, MD, PhD

Blood (2007) 110 (11): 2775.

https://doi.org/10.1182/blood.V110.11.2775.2775

Published: 2007

Journal Articles

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Konstantinos Zervas, MD, Dimitra Mihou, M.D., Irini Katodritou, M.D., Anastasia Pouli, M.D., Chrisanthi H. Mitsouli, M.D., Athanasios Anagnostopoulos, M.D., Souzana Delimbasi, M.D., Marie-Christine Kyrtsonis, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Panagiotis Zikos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 794.

https://doi.org/10.1182/blood.V108.11.794.794

Published: 2006

Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD

Blood (2004) 104 (11): 1438.

https://doi.org/10.1182/blood.V104.11.1438.1438

Published: 2004

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

NARROW

Morning Vs Bedtime Aspirin Intake in Patients with Essential Thrombocythemia

Thalidomide Combined with Interferons for the Treatment of Recurrent or Refractory Non-Hodgkin's Lymphoma

Low Dose Once Daily Oral Iron Treatment of Young Children with Nutritional Iron Deficiency Anemia

Therapeutic Superiority and Safety of Combined Hydroxyurea with Recombinant Human Erythropoietin Over Hydroxyurea in B-Thalassemia Intermedia Patients

Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM

Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.

Bortezomib Plus Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity: Results of a Multicenter Study.

Initial Cytoreductive Treatment with Thalidomide Plus Bolus Vincristine/Doxorubicin and Reduced Dexamethasone (T-bVAd) Followed by Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma.

Efficacy of the Novel Oral Iron Chelator Deferitrin in Metabolic Iron Balance Studies.

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Thalidomide for the Treatment of Low Risk Myelodysplasia.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only